Blocking the cascade of events that trigger autoimmune disease is a key focus in multiple sclerosis research. And a multidisciplinary team of investigators in Singapore says they have figured out one piece of the puzzle that could offer a new discovery pathway for the disease.
In the 11 years since the Singapore government created a biologics CMO to kickstart the local sector, a who's who of biopharma manufacturers have opened plants in the country. Baxter is among the latest to set up shop in Singapore and is already pushing ahead with expansion plans.
A drug-eluting patch developed by researchers at Nanyang Technological University in Singapore could offer a solution for patients with overgrown scar tissue.
Lincoln, NE, CRO Celerion has opened up shop in Singapore, following through on its efforts to tap the fast-growing Asian market for clinical research.
With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.
Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.
As drugmakers expand drug development and manufacturing around the world, logistics become important and often challenging. Suppliers, as well as drugmakers, have to figure out how to get ingredients and supplies to new destinations. Parexel is latching onto that opportunity with a new distribution center in Singapore, as well as expansion of operations in Billerica, MA.
Novartis is expanding a plant in Singapore and the international engineering and construction firm PM Group is helping.
Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products it is looking to get approved, and for that it says it needs some more production capacity.
Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis, GlaxoSmithKline and Amgen. Even Russia's Pharmstandard has an API facility there. Now AbbVie will join the group.